| Eligibility |
Inclusion Criteria:
- Ability to give informed consent
- 21 to 60 years of age (inclusive) at screening
- Race must be Chinese or Indian or Malay
- Overtly healthy males, as determined by medical history, physical examination and
laboratory results within normal reference range for the population or investigator
site, or results with acceptable deviations that are judged to be not clinically
significant by the investigator
- Males with stable medical problems that, in the investigator's opinion, will not
significantly alter the performance of the biomarker panel, will not place the subject
at increased risk by participating in the study, and will not interfere with
interpretation of the data.
- Not on any regular medications (western / traditional medicine)
- Nutritional supplements with established chemical composition that can be ascertained
and clearly recorded is acceptable. Participants have to stop taking nutritional
supplements at least 2 weeks before the start of study period.
- Reliable and willing to make themselves available for the duration of the study and
are willing to follow study procedures.
Exclusion Criteria:
- Female
- A current smoker, or has smoked in the past 2 years
- History or presence of current lipid and cardiovascular disorders, respiratory,
hepatic, renal, gastrointestinal, endocrine, lipid disorder, haematological,
malignancy or neurological disorders capable of significantly altering the performance
of the biomarker panel; or of interfering with the interpretation of data
- History of food allergies to test foods
- Regular use of medication that may affect glucose metabolism (e.g. steroids)
- History of type 1/type 2 diabetes and use of anti-diabetic medications in the past
- History of regular use of aspirin or vitamin C (both can affect glucose readings on
CGM)
- Regularly use known drugs or abuse within 3 years
- Known or ongoing psychiatric disorders within 3 years
- Have donated blood of more than 500 mL within 4 weeks of study enrolment
- Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
units per week (females):
- 1 unit = 12 oz or 360 mL of beer;
- 5 oz or 150 mL of wine;
- 1.5 oz or 45 mL of distilled spirits
- Uncontrolled hypertension (blood pressure [BP] >160/100mmHg)
- Active infection requiring systemic antiviral or antimicrobial therapy that will not
be completed prior to Study Day 1
- Treatment with any investigational drug, or biological agent within one (1) month of
screening or plans to enter into an investigational drug/ biological agent study
during the duration of this study
- Treatment with any investigational drug, or biological agent within one (1) month of
screening or plans to enter into an investigational drug/ biological agent study
during the duration of this study
- History of bleeding diathesis or coagulopathy
- Any of the following laboratory values at screening:
Fasting glucose >=126mg/dL(>=7mmol/L) or 2 hour post-prandial glucose >=200mg/dL
(>=11.1mmol/L)
- Clinically significant (as determined by investigator) abnormalities on laboratory
examination that will increase risk to the patient or interfere with data integrity
- Have any other conditions, which, in the opinion of the Investigator would make the
subject unsuitable for inclusion, or could interfere with the subject participating in
or completing the study
- Significant change in weight (+/- 5%) during the past month
- Any hospitalization or surgery during the 6 months before enrolment in study
- Participants with antibiotic use in past 2 months
|
